• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, July 30 Ranbaxy has announced the launch of its first authorised generic, the hypertension drug Isoptin, in the US.

The generic market for the drug (Verapamil SR) is valued at $122.2 million, with limited competition primarily from two other players, the company said. The drug will be launched through its wholly owned subsidiary, Ranbaxy Pharmaceuticals Inc, following an agreement with North Carolina-based FSC Laboratories Inc. Verapamil is a channel blocker indicated for management of hypertension and angina.

More Stories on : Announcements | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ranbaxy launches generic drug in US

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line